Absorbing Debate: Boston Sci, Abbott Differ On Whether The Future Of Stents Is To Disappear
This article was originally published in The Gray Sheet
Competing visions of the future of percutaneous coronary interventions were on display at TCT year, with Boston Scientific pushing its Synergy bioabsorbable polymer-coated, drug-eluting metal stent platform as the better long-term option to fully-resorbable scaffolds of the type Abbott is first out of the gate with.
You may also be interested in...
Abbott looks to Absorb GT1, the first fully bioresorbable coronary scaffold to gain FDA approval, to help accelerate growth. But it still has yet to be shown superior to conventional drug-eluting stents, and it also has metal stents with bioresorbable polymers to contend with.
An FDA panel meets March 15 to discuss Abbott's PMA for the firm's fully absorbable Absorb scaffold. Pre-meeting materials give a generally positive view of the device, but they highlight some elevated adverse-event rates.
Abbott Laboratories' Absorb GT1 Bioresorbable Vascular Scaffold System will soon be the first fully bioresorbable coronary scaffold to undergo FDA panel review. During a two-day Circulatory Systems Devices panel meeting in March, the panel will assess Absorb as well as Angel Medical System’s Angelmed Guardian System, an implantable monitor made to alert patients to coronary ischemia.